M.D., Vice President, Development, Oncology & Pharmacodiagnostics, Bristol-Myers Squibb
Dr. Averbuch established and leads Bristol-Myers Squibb’s (BMS) Pharmacodiagnostics Center of Excellence, whose mission is to drive precision medicine strategy across all therapeutic areas through integrated co-development and co-commercialization of diagnostic tests as companions to BMS medicines. Dr. Averbuch joined BMS in 2006. Previous responsibilities include leadership of: BMS’s immuno-oncology clinical collaborations and corporate strategic initiatives for Translational and Targeted Medicine, Oncology early strategy team (co-lead), executive sponsor for Oncology Transition Teams (execution of Phase 2 programs), and executive oversight for all late development and marketed oncology compound translational activities. Dr. Averbuch held positions at Merck, AstraZeneca, and Mount Sinai School of Medicine. He received his M.D. and Internal Medicine training from the University of Illinois, Chicago and Medical Oncology training at the National Cancer Institute, Bethesda, Maryland. Dr. Averbuch is active on committees and boards of several professional organizations and has authored 60+ peer reviewed publications and book chapters.
Session Abstract – PMWC 2017 Silicon Valley
As immunotherapies becomes a backbone of cancer treatment, biomarker assays will be critical to optimizing the use of immunotherapies as single agent or in combinations. This panel will explore how leading biopharma and academic researchers are identifying biomarkers and developing companion diagnostics for immuno-oncology.